DE3136031C2 - - Google Patents
Info
- Publication number
- DE3136031C2 DE3136031C2 DE3136031A DE3136031A DE3136031C2 DE 3136031 C2 DE3136031 C2 DE 3136031C2 DE 3136031 A DE3136031 A DE 3136031A DE 3136031 A DE3136031 A DE 3136031A DE 3136031 C2 DE3136031 C2 DE 3136031C2
- Authority
- DE
- Germany
- Prior art keywords
- active component
- pharmaceutical composition
- active
- formula
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- -1 2-benzoyloxy-3-tert-butylamino-propoxy Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- WQOWSHMABGCDSG-UHFFFAOYSA-N 4-(2,6-dimethyl-1,4-dihydropyridin-4-yl)-2,1,3-benzoxadiazole Chemical compound N=1ON=C2C=1C=CC=C2C1C=C(NC(=C1)C)C WQOWSHMABGCDSG-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 20
- 239000002876 beta blocker Substances 0.000 description 7
- 229940097320 beta blocking agent Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960002508 pindolol Drugs 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 5
- 229950009702 darodipine Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 3
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 3
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001778 cardiodepressive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229960001035 bopindolol Drugs 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8030226 | 1980-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3136031A1 DE3136031A1 (de) | 1982-04-08 |
| DE3136031C2 true DE3136031C2 (en, 2012) | 1993-02-11 |
Family
ID=10516152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813136031 Granted DE3136031A1 (de) | 1980-09-18 | 1981-09-11 | Pharmazeutische zusammensetzungen, wirksam gegen koronare herzkrankheiten und hohen blutdruck |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4510150A (en, 2012) |
| JP (1) | JPS5782315A (en, 2012) |
| AT (1) | AT381023B (en, 2012) |
| AU (1) | AU558670B2 (en, 2012) |
| BE (1) | BE890311A (en, 2012) |
| CA (1) | CA1177754A (en, 2012) |
| CH (1) | CH655658B (en, 2012) |
| DE (1) | DE3136031A1 (en, 2012) |
| FR (1) | FR2490092A1 (en, 2012) |
| GR (1) | GR75349B (en, 2012) |
| HU (1) | HU190355B (en, 2012) |
| IE (1) | IE51791B1 (en, 2012) |
| IL (1) | IL63854A (en, 2012) |
| IT (1) | IT1171533B (en, 2012) |
| NL (1) | NL8104246A (en, 2012) |
| NZ (1) | NZ198368A (en, 2012) |
| PH (1) | PH19782A (en, 2012) |
| PT (1) | PT73679B (en, 2012) |
| SE (1) | SE461014B (en, 2012) |
| ZA (1) | ZA816515B (en, 2012) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4414213A (en) * | 1982-03-22 | 1983-11-08 | Mead Johnson & Company | Dihydropyridyl cyclic imidate esters and their pharmaceutical use |
| JPS5978186A (ja) * | 1982-10-27 | 1984-05-04 | Yoshitomi Pharmaceut Ind Ltd | １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体 |
| DE3419131A1 (de) * | 1984-05-23 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung |
| SE455836B (sv) * | 1985-10-11 | 1988-08-15 | Haessle Ab | Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning |
| SE450087B (sv) * | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| DE3610037A1 (de) * | 1986-03-21 | 1987-09-24 | Schering Ag | Nifedipinkombinationspraeparat |
| SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3832470A (en) * | 1968-01-29 | 1974-08-27 | H Russek | Treatment of angina pectoris with a long-acting vasodilating agent and a beta adrenergic receptor blocking agent |
| ZA742728B (en) * | 1973-05-08 | 1975-04-30 | Simes | Pharmaceutical composition for the treatment of coronaric ailments |
| GB1513742A (en) * | 1975-01-31 | 1978-06-07 | Ici Ltd | 6-aryl-2,3,6,7-tetrahydro-5h-pyrrolo(1,2-a)imidazole derivatives processes for their manufacture and compositions containing them |
| GB1527543A (en) * | 1976-04-15 | 1978-10-04 | Degussa | Basically substituted xanthine derivatives |
| DK149855C (da) * | 1977-06-20 | 1987-04-21 | Sandoz Ag | Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater |
| CH639659A5 (de) * | 1978-12-18 | 1983-11-30 | Sandoz Ag | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
| DK525179A (da) * | 1978-12-18 | 1980-06-19 | Sandoz Ag | Fremgangsmaade til fremstilling af benzoxadiazoler og benzothiazoler |
| DE2949464A1 (de) * | 1978-12-18 | 1980-06-26 | Sandoz Ag | Benzoxadiazole und benzothiadiazole, ihre herstellung und verwendung |
-
1981
- 1981-09-09 CH CH582481A patent/CH655658B/de unknown
- 1981-09-11 BE BE1/10314A patent/BE890311A/fr not_active IP Right Cessation
- 1981-09-11 DE DE19813136031 patent/DE3136031A1/de active Granted
- 1981-09-14 FR FR8117448A patent/FR2490092A1/fr active Granted
- 1981-09-15 NL NL8104246A patent/NL8104246A/nl not_active Application Discontinuation
- 1981-09-16 NZ NZ198368A patent/NZ198368A/en unknown
- 1981-09-16 CA CA000385994A patent/CA1177754A/en not_active Expired
- 1981-09-16 GR GR66066A patent/GR75349B/el unknown
- 1981-09-16 IL IL63854A patent/IL63854A/xx not_active IP Right Cessation
- 1981-09-16 SE SE8105497A patent/SE461014B/sv not_active IP Right Cessation
- 1981-09-16 IT IT49305/81A patent/IT1171533B/it active
- 1981-09-16 PT PT73679A patent/PT73679B/pt not_active IP Right Cessation
- 1981-09-17 IE IE2157/81A patent/IE51791B1/en not_active IP Right Cessation
- 1981-09-17 JP JP56145659A patent/JPS5782315A/ja active Granted
- 1981-09-17 AU AU75443/81A patent/AU558670B2/en not_active Ceased
- 1981-09-17 AT AT0401181A patent/AT381023B/de not_active IP Right Cessation
- 1981-09-17 HU HU812689A patent/HU190355B/hu unknown
- 1981-09-18 PH PH26226A patent/PH19782A/en unknown
- 1981-09-18 ZA ZA816515A patent/ZA816515B/xx unknown
-
1983
- 1983-08-01 US US06/519,002 patent/US4510150A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GR75349B (en, 2012) | 1984-07-13 |
| IT8149305A0 (it) | 1981-09-16 |
| CA1177754A (en) | 1984-11-13 |
| FR2490092A1 (fr) | 1982-03-19 |
| ZA816515B (en) | 1983-04-27 |
| SE461014B (sv) | 1989-12-18 |
| AU7544381A (en) | 1982-04-01 |
| PT73679B (en) | 1983-05-11 |
| AU558670B2 (en) | 1987-02-05 |
| ATA401181A (de) | 1986-01-15 |
| PT73679A (en) | 1981-10-01 |
| SE8105497L (sv) | 1982-03-19 |
| HU190355B (en) | 1986-08-28 |
| IT1171533B (it) | 1987-06-10 |
| AT381023B (de) | 1986-08-11 |
| NZ198368A (en) | 1985-08-30 |
| IE51791B1 (en) | 1987-04-01 |
| NL8104246A (nl) | 1982-04-16 |
| PH19782A (en) | 1986-07-02 |
| IL63854A0 (en) | 1981-12-31 |
| IL63854A (en) | 1985-08-30 |
| DE3136031A1 (de) | 1982-04-08 |
| JPS5782315A (en) | 1982-05-22 |
| CH655658B (en, 2012) | 1986-05-15 |
| JPH0160009B2 (en, 2012) | 1989-12-20 |
| FR2490092B1 (en, 2012) | 1984-11-09 |
| US4510150A (en) | 1985-04-09 |
| BE890311A (fr) | 1982-03-11 |
| IE812157L (en) | 1982-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69930243T2 (de) | Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu | |
| US5149713A (en) | Use of baclofen for the treatment of angina pectoris | |
| DE60122928T2 (de) | Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat | |
| DE69734405T2 (de) | Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE3607381A1 (de) | Verwendung von diphenylhydantoin und seinen derivaten zur behandlung von immunerkrankungen | |
| DE3136031C2 (en, 2012) | ||
| DE69908421T2 (de) | Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol | |
| EP0224810B1 (de) | Antihypertensives Kombinationspräparat | |
| CH660556A5 (de) | Therapeutische zubereitung zur behandlung von kardiovaskulaeren krankheiten. | |
| DE60122252T2 (de) | Verfahren zur behandlung von neurodegeneration | |
| EP0508511B1 (de) | Erzeugnisse, enthaltend Verapamil und Trandolapril | |
| DE3880564T2 (de) | Arzneimittel zur behandlung von herzinsuffizienz. | |
| EP0013252B1 (de) | Mittel zur Senkung der Herzfrequenz | |
| DE2658500A1 (de) | Pharmazeutische praeparate mit kardioprotektiver wirkung | |
| DE2823268C2 (en, 2012) | ||
| IL97648A (en) | Stabilized 4-ethyl-2-hydroxyimono-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof | |
| DE2618500A1 (de) | Pharmazeutische zubereitung fuer die behandlung von bluthochdruck | |
| DE3410218A1 (de) | Tergurid als antihypertensivum | |
| DE3816937C2 (en, 2012) | ||
| DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
| DE68901711T2 (de) | Gegenmittel. | |
| DD283931A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen | |
| EP0169470A2 (de) | Neues Kombinationspräparat, Verfahren zu seiner Hestellung und seine Verwendung als Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8125 | Change of the main classification |
Ipc: A61K 31/44 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |